abstract |
A therapeutic combination, useful in the treatment ofnbenign prostatic hyperplasia, includes an inhibitor ofn17β-hydroxysteroid dehydrogenase activity and at leastnone further active ingredient selected from the groupncomprising antiestrogens, inhibitors of 5α-reductasenactivity and inhibitors of aromatase activity.nPharmaceutical compositions and kits useful for suchntreatment are also provided. |